References
- Lee Y, Baron ED. Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg. 2011;30:199–209
- Ibbotson SH. Adverse effects of topical photodynamic therapy. Photodermatol Photoimmunol Photomed. 2011;27:116–30
- Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2009;159:1245–66
- Schreml S, Gantner S, Steinbaue J, et al. Melanoma promotion after photodynamic therapy of a suspected Bowen’s disease lesion. Dermatology. 2009;219:279–81
- Maydan E, Nooothet PK, Goldman MP. Case reports: development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevolunic acid. J Drugs Dermatol. 2006;5:804–6
- Yarma S, Holt PJA, Anstey AV. Erthroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol. 2000;142:825–6
- Attili SK, Ibbotson SH, Fleming C. Role of a non-surgical therapies in the management of periocular basal cell carcinoma and squamous intra-epidermal carcinoma: a case series and review of the literature. Photoderm Photoimmun Photomed. 2012;28:68–79
- Kick G, Messer G, lewig G, et al. Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. Br J Cancer. 1996;74:30–6
- Mroz P, Hamblin MR. The immunosuppressive side of PDT. Photochem Photobiol Sci. 2011;10:751–6
- Thanos SM, Halliday GM, Damian DL. Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans. Br J Dermatol. 2012;167:631–6
- Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012;167:36–42
- Fuchs A, Marmur E. The kinetics of skin cancer: progressione of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007;33:1099–101